[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582501":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":48,"studyPopulation":48,"armGroups":54,"interventions":65,"overallOfficials":71,"centralContacts":76,"locations":85,"responsibleParty":191,"collaborators":48,"id":193,"slug":48,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":194,"sex":200,"minAge":48,"maxAge":48,"enrollmentInfo":201,"targetDuration":48,"studyType":204,"phases":205,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":175,"whyStopped":48,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":225},{"fullName":5,"class":6},"Odense University Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":32},[9],{"measure":10,"description":11,"timeFrame":12},"Fragility fractures","Incidence of fragility fractures during the study period","From enrollment to the end of the 3 year study period.",[14,18,22,25,29],{"measure":15,"description":16,"timeFrame":17},"Changes in bone mineral density (BMD)","Changes in lumbar spine and total hip BMD measured by dual energy X-ray arbsorptiometry. The three follow-up scans will be analyzed by a technician blinded to participant allocation, ie this person will not meet the patient and the patient will not be able see the results of the scans until the final study visit.","Baseline, 12, 24 and 36 months",{"measure":19,"description":20,"timeFrame":21},"Bone turn over marker (CTX)","Fasting blood samples will be performed during the study period to analyze changes in carboxy-terminal collagen crosslinks (CTX).","Blood samples are performed at baseline, 6, 12, 18, 24, and 36 months.",{"measure":23,"description":24,"timeFrame":21},"Bone turn over marker (P1NP)","Fasting blood samples will be performed during the study period to analyze changes in procollagen type I N-terminal propeptide (PINP).",{"measure":26,"description":27,"timeFrame":28},"Restart Criteria","The proportion of participants meeting restart criteria during the study period. Restart criteria is defined as: Participants experiencing boneloss exceeding 10% from baseline in any region, one clinical vertebral fracture, two low energy fractures (including morphometric vertebral fracture but excluding fractures of scull, fingers or toes) are withdrawn from the study and offered treatment with alendronate or zoledronic acid after new diagnostic work-up.","From enrollment to the end of the study period at 3 years",{"measure":30,"description":31,"timeFrame":12},"Adverse Events","At baseline a thoroughly physical examination of the participants and questioning concerning any conditions or diseases will take place. This way the investigators will be able to evaluate possible changes throughout the study. Patients will be interviewed about the occurrence of AEs at each visit from the first trial related activity after the subject has signed the informed consent. Subjects that experience adverse events or develop a disease during the trial period will be managed until the condition is cured or stationary. If this is not the case at the end of the study, subjects will be referred to a relevant physician, e.g. the general practitioner or a specialist, to be followed up.",[33,37,41],{"measure":34,"description":35,"timeFrame":36},"Osteoclastassay","Osteoclasts differentiation, formation, activity and response to Alendronate in cultures derived from peripheal blood at baseline and 12 months, from a subgroup of 35 from each arm (70 participants in total).","Baseline and 12 months",{"measure":38,"description":39,"timeFrame":40},"Molecular bone histology","Iliac crest bone biopsy specimens will be obtained to evaluate the effect of discontinuation of alendronate on cortical and trabecular bone resorption and formation by histomorphometry. These results will be compared with results of bone turnover markers. Biopsies will be obtained of maximum 35 from each treatment group at 12 and 36 months (in totalt 140 participants).","12 and 36 months",{"measure":42,"description":43,"timeFrame":44},"Epigenetic analysis","Epigenetic analysis of peripheal blood with focus on the degree of methylation.","Baseline",{"allocation":46,"interventionModel":47,"interventionModelDescription":48,"primaryPurpose":49,"observationalModel":48,"timePerspective":48,"maskingInfo":50},"RANDOMIZED","PARALLEL",null,"TREATMENT",{"masking":51,"maskingDescription":48,"whoMasked":52},"SINGLE",[53],"OUTCOMES_ASSESSOR",[55,61],{"label":56,"type":57,"description":58,"interventionNames":59},"Discontinuation of Alendronate","EXPERIMENTAL","Discontinuation of Alendronate treatment",[60],"Drug: Alendronate 70mg weekly",{"label":62,"type":63,"description":64,"interventionNames":48},"Control group","NO_INTERVENTION","The control group will continue Alendronate treatment, but shift to project-sponsored product (70 mg Alendronate weekly)",[66],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":48},"DRUG","Alendronate 70mg weekly","The intervention is discontinuation of Alendronate",[56],[72],{"name":73,"affiliation":74,"role":75},"Pernille Hermann, MD, PhD.","Odense Universitetshospital \u002F Odense University Hospital","PRINCIPAL_INVESTIGATOR",[77,81],{"name":73,"role":78,"phone":79,"phoneExt":48,"email":80},"CONTACT","+4523602366","pernille.herman@rsyd.dk",{"name":82,"role":78,"phone":83,"phoneExt":48,"email":84},"Lars Folkestad, MD, PhD.","+4529648537","lars.folkestad@rsyd.dk",[86,104,118,132,146,160,174],{"facility":87,"status":88,"city":89,"state":48,"zip":90,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":98,"contacts":99},"Aalborg University Hospital","NOT_YET_RECRUITING","Aalborg","9000","Denmark","DK",{"type":94,"coordinates":95},"Point",[96,97],9.9187,57.048,{"lat":97,"lon":96},[100],{"name":101,"role":78,"phone":102,"phoneExt":48,"email":103},"Peter Vestergaard","+4597660000","p.vestergaard@rn.dk",{"facility":105,"status":88,"city":106,"state":48,"zip":107,"country":91,"countryCode":92,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Bispebjerg Hospital","Copenhagen","2400",{"type":94,"coordinates":109},[110,111],12.56553,55.67594,{"lat":111,"lon":110},[114],{"name":115,"role":78,"phone":116,"phoneExt":48,"email":117},"Pia Eiken","+4525889530","pia.eiken.01@regionh.dk",{"facility":119,"status":88,"city":120,"state":48,"zip":121,"country":91,"countryCode":92,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Esbjerg Og Grindsted Sygehus","Esbjerg","6700",{"type":94,"coordinates":123},[124,125],8.45187,55.47028,{"lat":125,"lon":124},[128],{"name":129,"role":78,"phone":130,"phoneExt":48,"email":131},"Jeppe Gram","+4521338706","svs-forskning@rsyd.dk",{"facility":133,"status":88,"city":134,"state":48,"zip":135,"country":91,"countryCode":92,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Copenhagen University Hospital (Herlev)","Herlev","2730",{"type":94,"coordinates":137},[138,139],12.43998,55.72366,{"lat":139,"lon":138},[142],{"name":143,"role":78,"phone":144,"phoneExt":48,"email":145},"Jakob Praest Holm","+4538683868","jakob.praest.holm.01@regionh.dk",{"facility":147,"status":88,"city":148,"state":48,"zip":149,"country":91,"countryCode":92,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"Nordsjaellands Hospital (Hillerød)","Hillerød","3400",{"type":94,"coordinates":151},[152,153],12.30081,55.92791,{"lat":153,"lon":152},[156],{"name":157,"role":78,"phone":158,"phoneExt":48,"email":159},"Louise Tjelum","+4520485162","louise.tjelum@regionh.dk",{"facility":161,"status":88,"city":162,"state":48,"zip":163,"country":91,"countryCode":92,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Hvidovre Hospital","Hvidovre","2650",{"type":94,"coordinates":165},[166,167],12.47708,55.64297,{"lat":167,"lon":166},[170],{"name":171,"role":78,"phone":172,"phoneExt":48,"email":173},"Jens-Erik Bech Jensen","+4540427592","jens-erik.beck-jensen@regionh.dk",{"facility":5,"status":175,"city":176,"state":48,"zip":177,"country":91,"countryCode":92,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"RECRUITING","Odense","5000",{"type":94,"coordinates":179},[180,181],10.38831,55.39594,{"lat":181,"lon":180},[184,186,189],{"name":73,"role":78,"phone":79,"phoneExt":48,"email":185},"pernille.hermann@rsyd.dk",{"name":187,"role":188,"phone":48,"phoneExt":48,"email":48},"Freja Gram, MD","SUB_INVESTIGATOR",{"name":190,"role":188,"phone":48,"phoneExt":48,"email":48},"Lars Folkestad, MD, PhD",{"type":192,"investigatorFullName":48,"investigatorTitle":48,"investigatorAffiliation":48,"oldNameTitle":48,"oldOrganization":48},"SPONSOR","100582501",false,"NCT06864130","A Clinical Study on the Effect of Discontinuing Alendronate in Postmenopausal Women With Osteoporosis After a Treatment Period Without Fractures","The Alendronate Discontinuation Study","ALEXIS","Inclusion Criteria:\n\n* Female\n* Postmenopausal\n* Current treatment with Alendronate\n* Alendronate treatment \\>3 år AND no fracture OR\n* Alendronate treatment \\>5 år AND latest low energy fracture \\> 3 years ago\n\nExclusion Criteria:\n\n* T-score \\\u003C - 3,5 in hip (total hip or femoral neck) or lumbar spine\n* Treatment with systemic glucocorticoids, ongoing or within 12 months\n* Uncontrolled inflammatory disease\n* Active malignancy\n* eGFR \\\u003C 40 mL\u002Fmin\n* Atypical femur fracture (ever)\n* OsteoNecrosis of the Jaw (active)\n* Unable to give inform consent","FEMALE",{"count":202,"type":203},1400,"ESTIMATED","INTERVENTIONAL",[206],"PHASE4","The goal of this clinical trial is to study the effects of discontinuation of Alendronate treatment for three years. The participants are postmenopausal women with osteoporosis, who have had a treatment period without fractures. The study will answer:\n\n* What is the rate of fragility fractures during the study? The hypothesis is that discontinuation of Alendronate after a fracture-free period does not raise the 3-year fracture risk.\n* Are there predictors of significant bone loss after discontinuation of Alendronate? The hypothesis is that clinical, biochemical, cellular, or molecular characteristics can predict bone loss.\n\nResearchers will compare the outcomes of discontinuation of Alendronate with continuing treatment. Participants will be randomly assigned to a group.\n\nParticipants will:\n\n* Either take alendronate once weekly for three years OR discontinue their treatment\n* Visit the clinic at 6 and 18 months for blood samples\n* Visit the clinic at the start of the study and after 1, 2, and 3 years for bone scans and blood samples.",[209],"Osteoporosis in Post-menopausal Women",[211,212,213,214,215],"Alendronate","Discontinuation","Osteoporosis","Bone mineral density","post-menopausal","2025-02-28",{"date":218,"type":219},"2025-03-07","ACTUAL",{"date":221,"type":219},"2025-02-21",{"date":223,"type":203},"2029-09-15",{"name":5,"class":6},7]